News

Moleculin Expands U.S. Patents for Annamycin into Future

Moleculin Expands U.S. Patents for Annamycin into Future

Moleculin Strengthens Its Patent Portfolio for Annamycin

The company expands its global intellectual property coverage, prolonging claims to vital markets until June 2040.

HOUSTON – Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical firm focused on delivering innovative drug candidates for challenging cancers and viral infections, has announced that it has successfully obtained two new U.S. patents for Annamycin from the U.S. Patent and Trademark Office. These patents, numbered 12,257,261 and 12,257,262, are centered around the preparation and reconstitution of liposomal Annamycin, an exciting novel drug candidate.

The first patent, 12,257,261, describes methods for preparing the liposomal Annamycin lyophilizate, while the second, 12,257,262, details the processes involved in creating a liposomal suspension. The protection offered by these patents extends until June 2040 and is subject to adjustments for any delays in regulatory approval processes.

Currently in the clinical stage, Annamycin is being developed as the first anthracycline with a purported absence of associated cardiotoxicity. This treatment is geared towards patients suffering from acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets). Recent preclinical studies conducted at a prestigious cancer research center also suggest Annamycin's potential efficacy in treating various cancer types.

The Vision for Annamycin’s Development

Wally Klemp, the Chairman and CEO of Moleculin, expressed enthusiasm regarding the expansion of the company’s intellectual property as it relates to Annamycin. He noted that with the addition of these new patents, Moleculin now holds a total of four U.S. patents connected to Annamycin, complementing existing patents granted in Europe. Klemp emphasized the company's commitment to this essential treatment option as they continue to advance in their pivotal, adaptive Phase 3 MIRACLE clinical trial, with initial results anticipated in the latter half of the year 2025.

Importantly, Annamycin has received both Fast Track Status and Orphan Drug Designation from the FDA for treating relapsed or refractory AML, alongside Orphan Drug Designation for the treatment of STS lung mets. The European Medicines Agency (EMA) has also granted Orphan Drug Designation for Annamycin in treating relapsed or refractory AML, evidencing the global recognition of its therapeutic value.

Understanding Moleculin Biotech’s Mission

Moleculin Biotech, Inc. is dedicated to addressing serious global health issues through its innovative clinical solutions targeting difficult-to-treat tumors and viral diseases. The flagship program Annamycin is designed to overcome the limitations of existing anthracyclines by eliminating the cardiotoxicity that is typically encountered with these drugs. Ongoing discussions surrounding Annamycin's innovative design highlight its potential to revolutionize treatment for patients battling AML and STS lung metastases.

The company is progressing with the MIRACLE Trial (Moleculin R/R AML AnnAraC Clinical Evaluation), an adaptive design Phase 3 study evaluating the combination of Annamycin and cytarabine, collectively referred to as AnnAraC. Following positive outcomes from the Phase 1B/2 study (MB-106) and supportive feedback from the FDA, Moleculin is confident about its pathway to potential approval for Annamycin in treating AML.

Innovating Beyond Annamycin

In addition to Annamycin, Moleculin is actively developing WP1066, a promising Immune/Transcription Modulator with the capability to inhibit oncogenic transcription factors while stimulating natural immune responses, specifically targeting brain tumors and pancreatic cancer. The company is also investing in a variety of antimetabolites, including WP1122, which shows potential in treating viral pathogens alongside specified cancer indications.

Investing in Future Possibilities

Moleculin is committed to making strides in the competitive landscape of pharmaceuticals, especially in addressing unmet medical needs through innovative therapeutics. The granting of these new patents not only ensures exclusivity over Annamycin but also positions Moleculin as a forefront leader in oncological and viral treatments. With a robust patent portfolio and promising clinical data, the company is poised to influence the realm of cancer treatment significantly.

Frequently Asked Questions

What new patents has Moleculin received?

Moleculin received two new U.S. patents related to Annamycin, focusing on preparation and reconstitution methods for the liposomal form of the drug.

What is Annamycin used for?

Annamycin is being developed as a treatment for acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.

What is the MIRACLE trial?

The MIRACLE trial is a Phase 3 clinical trial evaluating the safety and efficacy of Annamycin in combination with cytarabine for treating relapsed or refractory AML.

What designations has Annamycin received from regulatory bodies?

Annamycin has Fast Track Status and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation from the EMA for AML treatments.

What other drugs is Moleculin developing?

Moleculin is also developing WP1066, an Immune/Transcription Modulator, and WP1122, aimed at treating pathogenic viruses and certain cancers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 70

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 72

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 61

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 116

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 60

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 248

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Mastering the Market: A Beginner's Guide to Stock Futures

Updated Category Markets Views 372

Introduction to Stock Futures A stock future is a kind of financial agreement that obligates the purchaser to buy, and the dealer to sell, a certain quantity of shares at a preset price on a specified future day. This sector of the finance market is very important for many players such as investors, daily traders, and financial analysts. Learning about stock futures can...

Continue Reading
Q2's New CFO, Jonathan Price, Steps into Key Role

Updated Category News Views 248

Q2 Holdings Welcomes a New Chief Financial Officer Q2 Holdings, Inc. (NYSE:QTWO), a leader in delivering digital transformation solutions for the financial services sector, has announced the noteworthy appointment of Jonathan A. Price as its new Chief Financial Officer. This strategic change is poised to take effect soon, marking an exciting chapter for the company. A...

Continue Reading
Metro-North Settlement of Over $182 Million Marks Legal Milestone

Updated Category News Views 138

Landmark Settlement in Metro-North Train Crash Case A recently published article in the New York Law Journal sheds light on a groundbreaking settlement of over $182 million related to one of the deadliest events in Metro-North Railroad history. This settlement, stemming from the tragic crash that resulted in the loss of five lives and injured many others, represents a...

Continue Reading
Advocacy for Injured Workers: A Call to Action at WSIB

Updated Category News Views 176

Injured Workers Rally for Change at the WSIB In a significant show of solidarity, injured workers, along with supporters, are uniting to demand improved conditions and benefits from the Workplace Safety Insurance Board (WSIB). This rally is not just about protest; it aims to highlight the dire circumstances faced by families of injured workers as students return to...

Continue Reading
eQ Plc Updates on Managerial Transactions and Business Growth

Updated Category News Views 282

eQ Plc's Recent Managerial Transactions eQ Plc recently provided vital updates regarding transactions involving key managerial figures. These notifications enhance the transparency of operations within the company. Key Individuals Involved Rettig Oy Ab is a notable entity associated with eQ Plc, and significant figures within this relationship include Tomas von Rettig and...

Continue Reading